Evaxion Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Evaxion Biotech has a total shareholder equity of $74.0K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.2M and $18.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.58m |
| Equity | US$74.00k |
| Total liabilities | US$18.93m |
| Total assets | US$15.19m |
Recent financial health updates
Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Financial Position Analysis
Short Term Liabilities: EVAX's short term assets ($4.6M) exceed its short term liabilities ($3.8M).
Long Term Liabilities: EVAX's short term assets ($4.6M) do not cover its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: EVAX is debt free.
Reducing Debt: EVAX has no debt compared to 5 years ago when its debt to equity ratio was 26.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVAX has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EVAX is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.